Clinical Trials

Carcinoma, Hepatocellular

NCT07521852 2026-04-13

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

40 enrolled

Phase 1/2 Not yet recruiting

Carcinoma, Hepatocellular, Neoplasms

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

100 enrolled

Carcinoma, Hepatocellular

NCT07331883 2026-03-27

Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)

35 enrolled

Carcinoma, Hepatocellular

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Phase 3 Completed

344 enrolled

Carcinoma, Hepatocellular

NCT06530251 2026-03-04

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Recruiting

280 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

60 enrolled

Carcinoma, Hepatocellular

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Carcinoma, Hepatocellular

NCT07186621 2025-09-22

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Phase 3 Recruiting

286 enrolled

Carcinoma, Hepatocellular

NCT06031285 2025-07-23

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

43 enrolled

Phase NA Not yet recruiting

Carcinoma, Hepatocellular

NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

234 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06860490 2025-03-26

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

164 enrolled

Carcinoma, Hepatocellular

NCT05713994 2025-03-25

CCGLC-001

Recruiting

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04297280 2025-02-27

TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma

Phase 2 Completed

25 enrolled

Carcinoma, Hepatocellular

NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Recruiting

Carcinoma, Hepatocellular

NCT06558227 2024-12-16

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

90 enrolled

Phase 2 Active not recruiting

Carcinoma, Hepatocellular

NCT03869034 2024-12-03

HAICPD1-HCC

40 enrolled

Carcinoma, Hepatocellular

NCT06313190 2024-11-18

HSBRT2402

140 enrolled

Carcinoma, Hepatocellular

NCT04954794 2024-10-31

TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)

Phase 2 Completed

29 enrolled

Carcinoma, Hepatocellular

NCT06664996 2024-10-30

Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT

33 enrolled

Carcinoma, Hepatocellular

NCT06070636 2024-08-09

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Phase NA Recruiting

Phase 1 Active not recruiting

Carcinoma, Hepatocellular, Liver Diseases

NCT04220944 2024-08-01

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

45 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT06512467 2024-07-22

Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT06090656 2024-07-03

BEST

88 enrolled

Carcinoma, Hepatocellular

NCT05717738 2024-06-13

CCGLC-008

Recruiting

Carcinoma, Hepatocellular

NCT04842565 2024-05-22

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

Phase 2 Completed

20 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT06089369 2024-04-30

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

360 enrolled

Carcinoma, Hepatocellular

NCT04618367 2024-03-06

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Phase NA Completed

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed

600 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT06285019 2024-02-29

Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma

65 enrolled

Phase 3 Not yet recruiting

Carcinoma, Hepatocellular

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

104 enrolled

Carcinoma, Hepatocellular

NCT05250843 2023-10-13

TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC

Phase 2/3 Unknown

90 enrolled

Carcinoma, Hepatocellular

NCT05010434 2023-09-21

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

46 enrolled

Carcinoma, Hepatocellular

NCT05992584 2023-09-14

Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC

Carcinoma, Hepatocellular

NCT06029829 2023-09-08

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

60 enrolled

Phase 2/3 Not yet recruiting

Carcinoma, Hepatocellular

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

668 enrolled

Carcinoma, Hepatocellular

NCT05971199 2023-08-02

Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

27 enrolled

Carcinoma, Hepatocellular

NCT05608200 2023-05-31

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Phase 3 Recruiting

427 enrolled

Carcinoma, Hepatocellular

NCT05616390 2023-03-21

Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT05029973 2023-02-08

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Carcinoma, Hepatocellular

NCT05225116 2023-02-08

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

Phase 1 Unknown

20 enrolled

Carcinoma, Hepatocellular

NCT05621499 2022-11-18

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

Phase NA Unknown

60 enrolled

Carcinoma, Hepatocellular

NCT05617430 2022-11-15

Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma

43 enrolled

Carcinoma, Hepatocellular

NCT04718909 2022-11-10

REGSIN

166 enrolled

Phase 2 Not yet recruiting

Carcinoma, Hepatocellular

NCT05507632 2022-08-19

Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma

48 enrolled

Carcinoma, Hepatocellular

NCT04174781 2022-06-09

Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

61 enrolled

Carcinoma, Hepatocellular

NCT05363722 2022-05-06

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Phase 1 Unknown

80 enrolled

Carcinoma, Hepatocellular

NCT05339581 2022-04-27

iPLENTY-pvtt

Phase NA Unknown

78 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

176 enrolled

Carcinoma, Hepatocellular

NCT04653389 2022-01-11

Perioperative Therapy for Hepatocellular Carcinoma

Phase 2 Terminated

10 enrolled